Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Refractory Blau Syndrome
NCT06660329Phase 4Enrolling by invitation
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in Blau syndrome, sponsored by Peking Union Medical College Hospital. Primary endpoint: Rate of remission or low disease activity at 6 months. Started Oct 2024; status: enrolling by invitation.
02
Drugs
03
Conditions
Blau syndrome
Beyond the preview
Go deeper on NCT06660329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660329.